LOX and cancer: To validate whether patients with elevated LOX family expression in specific cancer types were indeed resistant to immunotherapy, we screened independent datasets pertaining to programmed death 1 (PD‐1)/programmed death ligand 1 (PD‐L1) datasets from SKCM (GSE78220 and Riaz2017), LUAD (GSE135222), BLCA (IMvigor210CoreBiologies) and KIRC (NCT02684006 and PMID32472114).